Paradigm Therapeutics raises $12.5 million from Eshelman Ventures to support the development of SD-101, a topical therapy for Epidermolysis Bullosa, and plans for NDA submission in 2025.

May 06, 2025•3 months ago

Amount Raised

$12.5 Million

Mount PleasantTherapeuticsPharmaceuticalBiotechnologyHealth Care

Investors

Eshelman Ventures, Llc

Description

Paradigm Therapeutics, Inc. has announced a $12.5 million investment by Eshelman Ventures, LLC. This funding will support the completion of development activities for SD-101 (Zorblisa™) and an NDA submission in late 2025. Dr

Company Information

Company

Paradigm Therapeutics

Location

Mount Pleasant, South Carolina, United States

About

Paradigm Therapeutics, Inc. is a privately held, clinical-stage pharmaceutical company focused on developing innovative therapies to address critical medical needs in the treatment of rare diseases. Paradigm's main focus is the treatment of Epidermolysis Bullosa (EB). SD-101 (Zorblisa™), its leading therapy for the treatment of skin effects in patients with Epidermolysis Bullosa, has completed Phase II and Phase III clinical trials. SD-101 (Zorblisa™) is a topical cream that requires no special handling and can be stored at room temperature and has demonstrated potential to provide improvement in treating the severe skin effects seen in patients across all EB subtypes.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends